Overview

A Comparison Between Two Formulations of NN5401 in Healthy Subjects

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in the United States of America (USA). The aim of the trial is to compare the exposure of two formulations of insulin degludec/insulin aspart (NN5401) in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Insulin
Insulin Aspart
Insulin, Globin Zinc
Insulin, Long-Acting